Some of the approved drugs are synthetic versions of the natural hormones, such as trenbolone acetate and zeranol. Just like the natural hormone implants, before FDA approved these drugs, FDA required information and/or toxicological testing in laboratory animals to determine safe levels in the animal products that we eat (edible tissues). Furthermore, FDA required that the manufacturers demonstrate that the amount of hormone left in each edible tissue after treatment is below the appropriate safe level. As described above, a safe level is a level which would be expected to have no harmful effect in humans.
Human Growth Hormone is an injectable hormone that can be administered subcutaneously or intramuscularly. When injected subcutaneously, HGH carries a bioavailability of approximately seventy-five percent. When injected intramuscularly, HGH carries a bioavailability of approximately sixty-three percent. The mode of administration will also affect the half-life of the Somatropin hormone. When injected subcutaneously, it will carry a half-life of approximately hours. When injected intramuscularly, it will carry a half-life of approximately hours. While this is a rather short half-life regardless of the mode of administration, keep in mind the total effects far outlast these numbers due to the pronounced and significant increases in IGF-1 production that stretch far past the twenty-four hour mark.
Sometimes tumors on the pituitary or adrenal glands can contribute to a condition known as Cushing syndrome , which is characterized by high levels of cortisol in the blood. Individuals with Cushing syndrome will experience rapid weight gain in the face, abdomen, and chest. Often doctors will notice this because of the individual's slender arms and legs compared to the heavy weight in the core of the body. Cushing syndrome also causes a flushed face, high blood pressure, and changes in the skin. Osteoporosis and mood swings are also a factor considered with Cushing disease.